High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.

about

High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.

Item

http://www.wikidata.org/entity/Q41708722

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

High PHLPP1 expression levels ...... ents with lung adenocarcinoma.

@en

type

Item

label

High PHLPP1 expression levels ...... ents with lung adenocarcinoma.

@en

prefLabel

High PHLPP1 expression levels ...... ents with lung adenocarcinoma.

@en

P1476

High PHLPP1 expression levels ...... ents with lung adenocarcinoma.

@en

P2093

Dongqing Lv

http://www.w3.org/2001/XMLSchema#string

Haihua Yang

http://www.w3.org/2001/XMLSchema#string

Minhua Ye

http://www.w3.org/2001/XMLSchema#string

Wei Wang

http://www.w3.org/2001/XMLSchema#string

Xiaofeng Chen

http://www.w3.org/2001/XMLSchema#string

Youyou Xie

http://www.w3.org/2001/XMLSchema#string

P2860

PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice

Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Cancer statistics, 2010

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

P304

59000-59007

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19777

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28938613

http://www.w3.org/2001/XMLSchema#string

P932

5601709

http://www.w3.org/2001/XMLSchema#string